1. Lutathera

Novartis headquarters

Active ingredient: lutetium Lu 177 dotatate
Disease: gastroenteropancreatic neuroendocrine tumors
Peak sales estimate: $500 million to $2 billion
Approved: Jan. 2, 2018
Company: Novartis

The scoop: Novartis didn’t have to wait long for its $3.9 billion buyout of Advanced Accelerator Applications to pay off. Less than three months after agreeing to the pickup, the Swiss drugmaker got an FDA OK for Lutathera, which fit right into its portfolio alongside neuroendocrine tumor treatments Afinitor and Sandostatin. Since then, the product has been off to the races, racking up $56 million in third-quarter sales as part of what CEO Vas Narasimhan has called a “really explosive performance.” Through mid-October, Lutathera has been dosed 1,123 times across 85 U.S. prescribing centers. And on the reimbursement side, Novartis boasts 70% coverage of relevant lives. — Carly Helfand

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.